R&D expense · 2012–2025
Ultragenyx Pharmaceutical R&D expense
$750M+7.4% · FY2025
Ultragenyx Pharmaceutical (RARE) reported $750M in R&D expense for fiscal 2025, +7.4% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $750M | +7.4% | Open → |
| FY20242024-12-31 | $698M | +7.7% | Open → |
| FY20232023-12-31 | $648M | −8.2% | Open → |
| FY20222022-12-31 | $706M | +42.0% | Open → |
| FY20212021-12-31 | $497M | +20.6% | Open → |
| FY20202020-12-31 | $412M | +15.3% | Open → |
| FY20192019-12-31 | $357M | +21.6% | Open → |
| FY20182018-12-31 | $294M | +26.9% | Open → |
| FY20172017-12-31 | $232M | +26.4% | Open → |
| FY20162016-12-31 | $183M | +59.7% | Open → |
| FY20152015-12-31 | $115M | +149.6% | Open → |
| FY20142014-12-31 | $46.0M | +65.2% | Open → |
| FY20132013-12-31 | $27.8M | +120.1% | Open → |
| FY20122012-12-31 | $12.6M | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2012–2025 compound annual growth +36.9%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Ultragenyx Pharmaceutical R&D expense |url=https://companiesranked.com/en/company/ultragenyx-pharmaceutical/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Ultragenyx Pharmaceutical R&D expense. CompaniesRanked. https://companiesranked.com/en/company/ultragenyx-pharmaceutical/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-ultragenyx-pharmaceutical-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Ultragenyx Pharmaceutical R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/ultragenyx-pharmaceutical/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-057329 · February 18, 2026
{{cite web |title=Ultragenyx Pharmaceutical R&D expense — 10-K (0001193125-26-057329) |url=https://www.sec.gov/Archives/edgar/data/1515673/000119312526057329/rare-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-18}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.